From the publishers of JADPRO

CAR T-Cell Therapy Resource Center

Advertisement

Risk factors for CAR-T cell manufacturing failure among DLBCL patients: A nationwide survey in Japan

Last Updated: Friday, August 18, 2023

A retrospective study of 408 cases involving patients who received tisa-cel for treatment of DLBCL found manufacturing failure in 7.4% of patients. Repeated and short washout periods for bendamustine contributed to the risk of manufacturing failure.  

British Journal of Haematology
Advertisement
News & Literature Highlights
Advertisement
Advertisement